Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019) [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability trial of MK0633 in asthmatic children aged 12 to under 16, including plasma concentration profiling; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• MK0633

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Asthma | Phase 1 | Status: COMPLETED